← Leaderboards
Paula Gonzalez
Fundacion Inciensa
$28,686,384
Attributed
$28,686,384
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $23.6M · FY2016–17$25M$18.8M$12.5M$6.3M$0
'16
'17
Funding mix
By agency
NIH$28,686,384 · 3
By mechanism
N01$24,855,774 · 2
N02$3,830,610 · 1
Top collaborators
No co-investigators on record.
Most similar at Fundacion Inciensa
Same institution · by research overlap
- Paula Gonzalez-Maya$38,145,031
- Carolina Porras$11,742,990
- Rolando Herrero$14,003,389
- Charles Sanchez$787,124
- Ana Cecilia Rodriguez$4,601,397
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanEnrollmentDoseHuman Papilloma Virus VaccineFollow-UpParticipantVaccine TrialCosta RicaCommunitiesFundingBaseRandomizedProphylacticVaccinesContractsCervicalColposcopyHuman Papillomavirus 16Human Papilloma Virus InfectionEvaluationCollaborationsEfficacy EvaluationEffectivenessAntibodies
Grant awards (4)
IGF::OT::IGF TASK ORDER 1: ONE-DOSE TRIAL SETUP, ENROLLMENT AND IMMUNIZATION$20,939,852
N01 · FY2017 · CA · contact PI
HUMAN PAPILLOMAVIRUS (HPV) TYPE 16 VACCINE TRIAL IN COSTA RICA$2,638,379
N01 · FY2017 · CA · contact PI
IGF::OT::IGF EXIT OF CVT PARTICIPANTS AND PLANNING YEAR FOR ONE DOSE TRIAL$3,830,610
N02 · FY2016 · CA · contact PI
HUMAN PAPILLOMAVIRUS (HPV) TYPE 16 VACCINE TRIAL IN COSTA RICA$1,277,543
N01 · FY2016 · CA · contact PI